ECTRIMS 2024 | Investigating CAR T-cell therapy in the treatment of MS

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, discusses the potential use of chimeric antigen receptor (CAR) T-cell therapy to treat multiple sclerosis (MS). He mentions that there are ongoing studies investigating various therapies, including CD19 autologous CAR T-cells, and comments on the expected safety and efficacy of this potential one-time treatment. This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.